Last reviewed · How we verify
Dopaminergic medication
Dopaminergic medication is a Dopaminergic agent Small molecule drug developed by Universidad Francisco de Vitoria. It is currently in Phase 1 development.
Affects dopamine neurotransmission through interaction with dopamine receptors or dopamine metabolism pathways.
Dopaminergic medications are used to treat conditions such as Parkinson Disease, Idiopathic Parkinson Disease, and Schizophrenia, as indicated by ClinicalTrials.gov. The exact mechanism of action of dopaminergic medications is unknown, according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dopaminergic medication |
|---|---|
| Sponsor | Universidad Francisco de Vitoria |
| Drug class | Dopaminergic agent |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
Dopaminergic medications can work through various mechanisms including dopamine receptor agonism, dopamine reuptake inhibition, or modulation of dopamine synthesis and metabolism. Without specific molecular target information, the precise mechanism of this investigational agent remains unclear.
Approved indications
Common side effects
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms (PHASE2)
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- A Study of Pasireotide in People With Prolactinoma (PHASE2)
- Connectomic Guided DBS for Parkinson's Disease (NA)
- Short and Long-term Responses of PD Symptoms to Earstim (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dopaminergic medication CI brief — competitive landscape report
- Dopaminergic medication updates RSS · CI watch RSS
- Universidad Francisco de Vitoria portfolio CI
Frequently asked questions about Dopaminergic medication
What is Dopaminergic medication?
How does Dopaminergic medication work?
Who makes Dopaminergic medication?
What drug class is Dopaminergic medication in?
What development phase is Dopaminergic medication in?
Related
- Drug class: All Dopaminergic agent drugs
- Manufacturer: Universidad Francisco de Vitoria — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing